Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026
Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Fineline Cube Feb 11, 2026
Company Deals Digital

Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics

Fineline Cube Feb 11, 2026
Company Deals

Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China

Fineline Cube Feb 10, 2026
Company Deals

Overseas Pharma Partners with South American Pharma Group on Global Extended-Release Drug Development

Fineline Cube Feb 10, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial

Fineline Cube Feb 11, 2026
Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Fineline Cube Feb 11, 2026
Company

Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model

Fineline Cube Jan 28, 2025

On January 27, 2025, the Hong Kong Stock Exchange (HKEX) website displayed that Suzhou Vigonvita...

Company Deals

CStone Pharmaceuticals Partners with SteinCares for Sugemalimab Commercialization in Latin America

Fineline Cube Jan 27, 2025

CStone Pharmaceuticals (HKG: 2616), a China – based biopharmaceutical company focused on oncology drug development,...

Company Medical Device

MicroPort’s Fireliums Receives NMPA Approval for Coronary Bifurcation Stenosis Treatment

Fineline Cube Jan 27, 2025

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from...

Company Medical Device

MicroPort’s TomaHawk Intravascular Shock Wave Therapy Device Approved by NMPA

Fineline Cube Jan 27, 2025

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from...

Company Drug

FDA Clears sBLA for Eisai and Biogen’s Leqembi Maintenance Dosing

Fineline Cube Jan 27, 2025

Partners Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that the...

Company Deals Medical Device

Jiangsu Yuyue Partners with Inogen for International Distribution and R&D

Fineline Cube Jan 27, 2025

China-based Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (SHE: 002223) has struck a partnership...

Company Drug

Guangzhou Innogen’s Efsubaglutide Alfa Approved by NMPA for Type 2 Diabetes

Fineline Cube Jan 27, 2025

China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd, a biopharma focused on metabolic diseases, has announced...

Company Drug

MSD and Eisai’s Keytruda/Lenvima Combo Shows Promise in Gastroesophageal Cancer Study

Fineline Cube Jan 26, 2025

Partners Merck, Sharp & Dohme (MSD, NYSE: MRK) and Eisai (TYO: 4523) have announced the...

Policy / Regulatory

NHSA Targets Low-Volume Drugs in National Reimbursement List

Fineline Cube Jan 26, 2025

The National Healthcare Security Administration (NHSA) in China has released a list of 131 drugs...

Company Drug

Novo Nordisk’s Amycretin Shows Promising Weight Loss Results in Phase Ib/IIa Study

Fineline Cube Jan 26, 2025

Denmark – based pharmaceutical giant Novo Nordisk A / S (NYSE: NVO) has announced topline...

Company Deals

Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing

Fineline Cube Jan 26, 2025

Jiangsu Vcare PharmaTech Co., Ltd., a China – based high – tech pharmaceutical company, has...

Company Deals

GeneQuantum Secures $13 Billion Deals with Biohaven and AimedBio for ADC Development

Fineline Cube Jan 26, 2025

Suzhou based biotech firm GeneQuantum has announced a series of major commercial cooperation pacts worth...

Company Deals

Sinopharm Partners with Biogen for Comprehensive Service Agreement

Fineline Cube Jan 26, 2025

China-based Sinopharm Group Co., Ltd (HKG: 1099) has entered into a strategic partnership with US-based...

Company Drug

Boehringer Ingelheim’s Nerandomilast Granted Priority Review for IPF in China

Fineline Cube Jan 26, 2025

German pharmaceutical giant Boehringer Ingelheim has announced that the Center for Drug Evaluation (CDE) of...

Company Deals

Mirxes Holding Files for Hong Kong IPO with Focus on miRNA Test Kits

Fineline Cube Jan 26, 2025

Mirxes Holding Company Ltd, a Singapore – headquartered RNA technology company, has received a filing...

Company Drug

Shenzhen Kangtai Halts COVID-19 Vaccine Development Amid Market Shifts

Fineline Cube Jan 26, 2025

Shenzhen based biopharmaceutical company Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the...

Company Medical Device

Huadong Medicine’s Ellansé M Filing Accepted by China’s NMPA

Fineline Cube Jan 26, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that its market filing for the...

Company Digital Drug

China Medical System Partners with MabGeek for Innovative Drug MG-K10

Fineline Cube Jan 26, 2025

China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek...

Company Drug

BioCity Biopharma Launches Phase III Study for Kidney Disease Drug SC0062

Fineline Cube Jan 25, 2025

BioCity Biopharma, a leading biopharmaceutical company, has announced the initiation of a Phase III clinical...

Company Deals

ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline

Fineline Cube Jan 24, 2025

ConjuStar, a specialist in X-Drug conjugates (XDCs) based in Tianjin, has reportedly raised RMB100 million...

Posts pagination

1 … 177 178 179 … 622

Recent updates

  • China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million
  • Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial
  • Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder
  • Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device
  • Eisai Biogen’s LEQEMBI Subcutaneous Autoinjector Wins NMPA Priority Review in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Company Drug

Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial

Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.